- Home
- SPT vs OCUL Comparison
SPT vs OCUL Comparison
Compare SPT & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- OCUL
- Stock Information
- Founded
- SPT 2010
- OCUL 2006
- Country
- SPT United States
- OCUL United States
- Employees
- SPT N/A
- OCUL N/A
- Industry
- SPT Computer Software: Prepackaged Software
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- SPT Technology
- OCUL Health Care
- Exchange
- SPT Nasdaq
- OCUL Nasdaq
- Market Cap
- SPT 1.6B
- OCUL 1.4B
- IPO Year
- SPT 2019
- OCUL 2014
- Fundamental
- Price
- SPT $30.32
- OCUL $8.52
- Analyst Decision
- SPT Buy
- OCUL Strong Buy
- Analyst Count
- SPT 14
- OCUL 8
- Target Price
- SPT $48.00
- OCUL $16.50
- AVG Volume (30 Days)
- SPT 581.7K
- OCUL 929.4K
- Earning Date
- SPT 11-07-2024
- OCUL 11-14-2024
- Dividend Yield
- SPT N/A
- OCUL N/A
- EPS Growth
- SPT N/A
- OCUL N/A
- EPS
- SPT N/A
- OCUL N/A
- Revenue
- SPT $392,402,000.00
- OCUL $61,442,000.00
- Revenue This Year
- SPT $22.76
- OCUL $15.49
- Revenue Next Year
- SPT $16.96
- OCUL $13.31
- P/E Ratio
- SPT N/A
- OCUL N/A
- Revenue Growth
- SPT 26.70
- OCUL 6.45
- 52 Week Low
- SPT $25.05
- OCUL $2.15
- 52 Week High
- SPT $68.41
- OCUL $11.78
- Technical
- Relative Strength Index (RSI)
- SPT 59.62
- OCUL 31.56
- Support Level
- SPT $27.79
- OCUL $8.51
- Resistance Level
- SPT $29.94
- OCUL $8.99
- Average True Range (ATR)
- SPT 1.46
- OCUL 0.60
- MACD
- SPT 0.23
- OCUL -0.30
- Stochastic Oscillator
- SPT 85.59
- OCUL 10.20
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. The firm generates majority revenue from software subscriptions.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.